The abstract is read at the publisher; the summary is JClub's.
A benzimidazole-enabled LiCO lipid-duplex siRNA conjugate achieves >90% target knockdown in mouse skeletal muscle, heart, aorta, and adipose after one systemic dose.
- Why it matters: Extending siRNA beyond liver uptake is a key barrier for RNA therapeutics, limiting treatment options for extrahepatic and localized diseases.
- What they did: LiCO was synthesized as a single chemical entity via solid-phase chemistry; screening identified a 5'-passenger C16 conjugate, and CD36-knockout mice tested uptake drivers.
- The result: In mice, ≥50% silencing persisted for 6 months with measurable activity at 9 months, while hepatic silencing was transient; in cynomolgus macaques, two IV doses produced ~90% myostatin mRNA knockdown and 60–70% protein suppression through day 98 with muscle hypertrophy and no adverse findings.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.